Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-322 +/- Irinotecan in Recurrent Glioblastoma Multiforme
NCT00562419Phase 2Unknown
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2007
- Primary completion
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegdinetanib in glioblastoma multiforme (GBM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of CT-322 alone or with irinotecan and Progression-free survival at 6 months. Status: unknown.
02
Drugs
pegdinetanib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00562419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562419.